Schedule of Deferred Tax Assets and Liabilities [Table Text Block] |
|
|
As of December 31, |
|
|
|
2021 |
|
|
2020 |
|
Deferred tax assets: |
|
|
|
|
|
|
|
|
Net operating loss carryforwards |
|
$ |
36,793,074 |
|
|
$ |
34,365,098 |
|
R&D credit carryforwards |
|
|
9,501,299 |
|
|
|
9,301,709 |
|
Stock compensation |
|
|
481,098 |
|
|
|
419,654 |
|
Intangibles |
|
|
567,213 |
|
|
|
616,926 |
|
Disallowed interest expense |
|
|
851,247 |
|
|
|
852,338 |
|
Temporary differences |
|
|
305,974 |
|
|
|
267,312 |
|
Deferred tax assets before valuation allowance |
|
|
48,499,905 |
|
|
|
45,823,037 |
|
Valuation allowance |
|
|
(48,499,905 |
) |
|
|
(45,823,037 |
) |
Net deferred tax assets |
|
$ |
— |
|
|
$ |
— |
|
|
Summary of Tax Credit Carryforwards [Table Text Block] |
|
|
|
|
|
As of December 31, 2021 |
|
Generated |
|
Expiration |
|
|
U.S. Net Operating Loss Carryforwards |
|
|
U.S. R&D Credit Carryforwards |
|
2001 |
|
2021 |
|
|
$ |
— |
|
|
$ |
39,128 |
|
2002 |
|
2022 |
|
|
|
— |
|
|
|
5,350 |
|
2003 |
|
2023 |
|
|
|
— |
|
|
|
2,905 |
|
2004 |
|
2024 |
|
|
|
— |
|
|
|
22,861 |
|
2005 |
|
2025 |
|
|
|
— |
|
|
|
218,332 |
|
2006 |
|
2026 |
|
|
|
— |
|
|
|
365,541 |
|
2007 |
|
2027 |
|
|
|
— |
|
|
|
342,898 |
|
2008 |
|
2028 |
|
|
|
— |
|
|
|
531,539 |
|
2009 |
|
2029 |
|
|
|
— |
|
|
|
596,843 |
|
2010 |
|
2030 |
|
|
|
— |
|
|
|
1,094,449 |
|
2011 |
|
2031 |
|
|
|
— |
|
|
|
1,950,744 |
|
2012 |
|
2032 |
|
|
|
18,898,490 |
|
|
|
468,008 |
|
2013 |
|
2033 |
|
|
|
37,450,522 |
|
|
|
681,772 |
|
2014 |
|
2034 |
|
|
|
34,088,874 |
|
|
|
816,116 |
|
2015 |
|
2035 |
|
|
|
25,073,846 |
|
|
|
492,732 |
|
2016 |
|
2036 |
|
|
|
15,581,209 |
|
|
|
262,257 |
|
2017 |
|
2037 |
|
|
|
— |
|
|
|
387,892 |
|
2018 |
|
N/A |
|
|
|
— |
|
|
|
197,547 |
|
2019 |
|
N/A |
|
|
|
11,245,808 |
|
|
|
213,065 |
|
2020 |
|
N/A |
|
|
|
11,018,478 |
|
|
|
222,842 |
|
2021 |
|
N/A |
|
|
|
10,746,123 |
|
|
|
238,717 |
|
Total carryforwards |
|
|
$ |
164,103,350 |
|
|
$ |
9,112,411 |
|
|
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] |
|
|
2021 |
|
|
2020 |
|
|
|
Amount |
|
|
% |
|
|
Amount |
|
|
% |
|
Benefit at statutory rate |
|
$ |
(2,460,126 |
) |
|
|
(21.0 |
)% |
|
$ |
(2,390,972 |
) |
|
|
(21.0 |
)% |
Adjustments to valuation allowance |
|
|
2,676,868 |
|
|
|
22.9 |
% |
|
|
2,521,625 |
|
|
|
22.1 |
% |
Adjustments to R&D credit carryforwards |
|
|
(199,589 |
) |
|
|
(1.7 |
)% |
|
|
(151,129 |
) |
|
|
(1.3 |
)% |
Permanent items and other |
|
|
(1,110 |
) |
|
|
(0.1 |
)% |
|
|
20,476 |
|
|
|
0.2 |
% |
Provision (benefit) per financial statements |
|
$ |
16,043 |
|
|
|
|
|
|
$ |
— |
|
|
|
|
|
|